NASHVILLE, TN (WSMV) - The FDA finds the Moderna Vaccine “safe and effective,” and this vaccine is being studied in Vanderbilt Medical Center trials.

“I would imagine Moderna can start shipping next week,” Dr. William Schaffner, Division of Infectious Diseases at VUMC, said

Schaffner said Moderna’s Vaccine would be given the yay or nay this weekend for emergency approval.

“We’ll go to the CDC’s advisory committee on immunization practices, and they will make their recommendations just as they did with the Pfizer Vaccine,” Schaffner said.

Moderna could be the second vaccine to be administered to thousands across the country. Like the Pfizer Vaccine, it’s given in two separate doses—given weeks apart. Dr. Schaffner said there’s one major difference that may allow the Moderna Vaccine to be given to even more people.

“I think this vaccine doesn’t require all the stringent, very, very low-temperature requirements that the Pfizer Vaccine does,” Schaffner said. “So, the Moderna Vaccine I think will be more widely distributed to pharmacies, doctors’ offices and can be used in rural areas.”

Currently, the analysis done by the FDA says Moderna’s Vaccine is less effective in older people. For people ages 18 to 65, the effectiveness is 96%, compared to 86% of 65 and older. is now with you on the go! Get the latest news updates and video, 4WARN weather forecast, weather radar, special investigative reports, sports headlines and much more from News4 Nashville.

>> Click/tap here to download our free mobile app. <<

Copyright 2020 WSMV (Meredith Corporation). All rights reserved.

Recommended for you

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.